On June 15, 2026, the FDA accepted the Biologics License Application (BLA) for ozekibart (INBRX-109) for treating unresectable or metastatic conventional chondrosarcoma. The FDA reported no filing review issues and set a PDUFA goal date of April 14, 2027. Inhibrx Biosciences is a biotechnology company that develops therapeutic proteins.
